Loading...
ROCO
4186
Market cap37mUSD
Nov 13, Last price  
13.00TWD
Name

Taiwan Advance Bio-Pharmaceutical Inc

Chart & Performance

D1W1MN
ROCO:4186 chart
P/E
51.15
P/S
3.30
EPS
0.25
Div Yield, %
Shrs. gr., 5y
3.49%
Rev. gr., 5y
11.47%
Revenues
354m
+12.09%
205,802,000235,574,000243,363,000318,237,000315,984,000354,173,000
Net income
23m
P
-174,667,000-86,391,000-118,525,0003,170,000-10,682,00022,875,000
CFO
8m
-33.95%
-150,752,000-50,325,000-48,082,000-20,593,00012,607,0008,327,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA, rapid, and chemical test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and polyclonal antibody products. It also offers abused drugs rapid tests; provides cell banking services for newborn and adult stem cells storage; and operates drug testing center for urine drug test, hair drug test, and identification of drug abuse. The company was founded in 1989 and is based in New Taipei City, Taiwan.
IPO date
Nov 27, 2012
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT